Leo Pharma’s latest “hackathon” brought together scientists and entrepreneurs to find dermatology solutions for people of color.
The third “Hacking Dermatology Innovation Challenge” tasked participants to focus on the specific challenges faced by “patients with skin of color.” The partnership between Leo’s research and development unit and nonprofit skin advocacy group Advancing Innovation in Dermatology (AID) named five winning teams over the weekend.
Research has shown that diagnosing skin of color can be more difficult because of darker pigmentation as well as differences in the way inflammation presents. The “Hacking Dermatology” contest that ran through Sunday hopes to help with the issue.
Some of the ideas Leo was looking for included shortening diagnostic delays, making diagnoses more accurate, offering better personalized care, making clinical trials more diverse and providing empowerment and education that could lead to equity in technology advancements, Michael Sierra, vice president of the Leo Science & Tech Hub, said.
MIT Hacking Medicine is also part of this year’s challenge. While this is the third “Hacking Dermatology” challenge, it’s the first time the challenge was completely virtual due to the COVID-19 pandemic.
“What’s really cool about entrepreneurs and scientists is that most of us are introverts, right, so working in a virtual setting isn’t the biggest challenge. We’ve seen quite a good turnout,” Sierra said.
The three-day event began with a pitch session. Contributors then presented and competed over two days, with the winner announced Oct. 25.
The winning teams received $15,000 in grants and a chance to move to an advanced challenge with another $25,000 prize. The teams are mentored by volunteers from a variety of backgrounds and get access to resources that could potentially bring the winning projects to life.
The project was born in 2018 after Leo brought together key opinion leaders and scientists to consider innovation challenges in the field. Hacking Dermatology was created as a way to help healthcare professionals, entrepreneurs and others solve the real problems they’ve discovered, William Ju, M.D., one of the challenge founders and president and founder of AID, said.
“You can come to look and promote your idea, refine it, find key members and move it forward into something that is very tangible,” he said.
Over the past few years, Leo Pharma has purchased dermatology businesses including Bayer’s prescription unit and Astellas’ portfolio. Leo also markets plaque psoriasis drugs Enstilar and Taclonex.
by Sharon Klahr Coey
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.